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1. Introduction 
The most recent investigation from the World Health Organization's International Agency 
for Research on Cancer (WHO/IARC) indicates that the incidence of malignant tumors is 
rising throughout the world. In 2008, 7.6 million people died of malignant tumors and 64% 
of them occurred in developing countries(Jemal et al, 2011). Particularly, the status on the 
treatment of tumors is extremely harsh in China since both incidence and mortality of 
malignant tumors in China is drastically rising in the past two decades (Zhang et al, 2008). It 
is expected that this increasing tendency will continue in China in the next two 
decades(Xv&Dong,2003). There is no doubt that tumor therapy will be for long term a hot 
topic in the field of life and medicine in the feature.  
The extensive understanding of molecular mechanisms underlying tumor development and 
progression provides more deep insights that tumor is a genetic disease. It appears that the 
correction of defective genes would likely be a new approach for the treatment of tumors 
(Wang et al, 2010). RNA interference (RNAi) is a double-stranded RNA-induced gene 
silencing process, by which RNA can specifically silence complementary mRNA in the cells. 
Fire et al. for the first time discovered this phenomenon in the cells of rod-shaped 
nematomorpha(Fire et al, 1998), for which he was awarded the Nobel Prize in Physiology or 
Medicine in 2006. Further studies found that RNAi exists in almost all multi-cellular 
organisms and plays an important role in defense against double-stranded RNA 
virus(Hannon,2002). Also, RNAi-based tumor therapy in animal models has demonstrated 
that RNAi is a powerful means for tumor therapy(López-Fraga et al, 2009;Davis et al, 2010; 
Koldehoff& Elmaagacli,2009; Maples et al, 2009).  
This chapter aims to review current progress in RNAi for tumor therapy. The mechanisms 
underlying RNAi-induced gene silencing pathway were briefly described in the first section. 
Next, the application of RNAi targeting different tumor-related genes was summarized in 
detail. Finally, recent achievement of RNAi-based tumor therapy in clinical trials was also 
reviewed.  
2. Mechanisms of RNAi 
The RNAi phenomenon was first found in antisense hybridization of antisense RNA and 
mRNA. However, further studies showed that the sense strand could also result in reduced 
gene expression (Guo& Kemphues,1995). Subsequent studies demonstrated that each strand 
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of dsRNA can induce RNAi, but only few types of dsRNA can lead to potent interference 
effect (Fire et al, 1998). The molecules that can trigger RNAi include small interference RNA 
(siRNA), microRNA (miRNA) and small hairpin RNA (shRNA). The mechanisms of RNAi 
triggered by these molecules are not exactly the same.  
2.1 Mechanisms of siRNA 
SiRNA is a class of dsRNA molecules with 20-25 nucleotides in length. When dsRNA enters 
cells, it can be lysed into siRNA by Dicer enzyme. On the other hand, dsRNA proliferates in 
the presence of RNA-directed RNA polymerase (RdRP) and is then lysed in the presence of 
Dicer enzyme. Double-stranded siRNA is processed by Dicer into single-stranded siRNA, 
which can form a complex via binding with some related proteins. This complex can bind 
simultaneously with complementary mRNA, thereby inducing mRNA lysis.  
SiRNA-induced RNAi is initiated from a cleavage program. Long dsRNA is first cleaved by 
Dicer into siRNAs in cytoplasm. The Dicer contains an N-terminal helicase domain, a 
PAZうPiwi/Argonaute/ZwilleえRNA domain, two RNAase III domains, and a dsRNA 
binding domain (dsRBD) (Bernstein et al, 2001). The RNA helicase domain sequence is 
highly stable and N-terminal and C-terminal are core components. The N-terminal has an 
ATP-binding and hydrolysis subunit, and the C-terminal contains a RNA-binding subunit. 
With these subunits, the RNA helicase domain can play a helicase function by making use of 
the energy provided by ATP (Ma et al, 2004). The PAZ domain of Dicer can specifically 
recognize and bind with the 5’ phosphate bond with two nucleotide protrusions in the 
dsRNA3’ end (Cordin et al, 2006). There is a long ┙-helix between the PAZ domain and the 
RNase III domain, and this helix is encircled by a conserved N-terminal protein, forming a 
platform domain consisting of an anti-parallel ┚-sheet and three ┙-helixes, and at both ends 
of the platform domain are hinge1 and hinge 2 as a polypeptide chain to hinge with the PAZ 
domain and the RNase III domain respectively. Of them, hinge1 contains a Pro-266 kink, 
which enables the PAZ domain to move a 5Å distance. Unlike hinge 1, hinge 2 does not 
have the link, but it can enable the RNase III domain to make a 5° rotation along the long 
axis of the Dicer molecule. Therefore, Dicer is able to adapt to substrates of different shapes 
by regulating the platform, hinge 1 and hinge 2 for the purpose of cleaving different 
substrates (Macrae et al, 2006). Each RNase III domain possesses two active centers, and each 
center has the activity of cleaving the phosphodiester bond, and can cleave dsRNA into 
small RNA with two nucleotide protrusions in the dsRNA3’ end, which is the typical 
characteristic of the RNase III product (Collins&Cheng,2005). Although Dicer contains two 
RNase III domains and four active cleavage centers, each RNase III domain provides only 
one active center for cleavage. The distance between the active centers of the two RNase III 
domains is 65Å apart, equaling 25 bp RNA in length. This structural characteristic ensures 
Dicer to specifically produce small RNA of 21~25 bp in length, and enables it to change the 
length of the cleaved product by mirco-regulating the distance between the two RNase III 
domains (Blaszczyk et al, 2001). In the C-terminal of Dicer is the dsRBD that contains about 
70 amino acids existing in the form of ┙┚┚┚┙, of which the ┙-helix is close to one side of ┚-
sheet in a reverse and parallel form (Hallegger et al, 2006). dsRBD and dsRNA interact with 
each other across a width of 16 bp, which is just the distance between the two small adjacent 
grooves and the large groove on one side of ┙-dsRNA(Wu et al, 2004). This interacting 
region can be further divided into three small regions. Region 1: the four 2’-OH at the first 
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small groove of dsRBD N-terminal ┙-helix connect with five nucleotides of RNA. Region 2: a 
stem loop between ┚1and ┚2 of dsRBD connects with 2-5 nucleotides of RNA in the second 
small groove through 2’-OH. Region 3: the ┙-helix at the C-terminal of dsRBD travels across 
the large groove of RNA and connects with the phosphodiester bond in RNA (Ryter & 
Schultz, 1998). 
The long dsRNA that enters cells is processed by Dicer into double-stranded siRNA, and 
then bind with Dicer, trans-activitor response region RNA-binding protein (TRBP), and 
protein kinase R (PKR)-activating protein (PACT) to form a RNA-induced silencing complex 
(RISC) (Hammond et al, 2000). 
RNAi induced by completely processed single-stranded siRNA (mostly exogenous) can be 
directly installed into RISC without the participation of TRBP/PACT-Dicer complex. 
However, in other RNAi processes, RNAi cannot be installed into RISC without the 
participation of TRBP/PACT-Dicer complex. Through TRBP/PACT, siRNA-TRBP/PACT-
Dicer complex binds with Argonaute 2 (Ago2/EIF2C2) to form RISC loading complex (RLC) 
(Robb&Rana,2007). RLC initiates disentanglement of siRNA and distinguishs the guide 
strand and the passenger strand. The guide strand 5’-end has the property of a low 
thermodynamic stability and can be bound into RISC by priority(Tomari et al, 2004). The 
passenger strand is cleaved by Ago 2 and separated from RLC (Matranga et al, 2005). The 
specific sequence for binding between the RISC-mediated RNA guide strand and target 
mRNA is mainly located in the "seed" or "core" region of 2-8 nucleotides of siRNA 5’-end 
(Ma et al, 2005). mRNA oligonucleotide is cleaved from the middle in the presence of Ago2 
and loses the expression function (Schwarz et al, 2004; Hammond,2005). 
Ago 2 is the only protein that has the endonuclease function in RLC, mainly consisting of an 
N-terminal domain, a PAZ domain, a middle domain and a PIWI domain, of which the N-
terminal domain, middle domain and PIWI domain form a crescent basin structure, with 
one “arm” supporting the PAZ domain above the “basin” (Song et al, 2004;Yuan et al, 2005). 
This structure forms a groove carrying positive charge. The N-terminal domain and PIWI 
domain form the small groove, which can bind with nucleic acid. The PAZ domain and the 
crescent “basin” form the large groove, which can contain double strands and locate the 
easily broken phosphate bond directly to the catalytic site of Rnase H sheet on the PIWI 
domain. Ago 2 can melt siRNA, forming single-stranded antisense siRNA complementary to 
target mRNA. The Rnase H PIWI domain of Ago 2 is located in the 5’-end, and the PAZ 
domain can recognize siRNA3’-end. When siRNA binds with complementary target mRNA, 
Ago 2 begins digesting mRNA, forming RNA fragments with 5’-carboxylate and 3’-
phosphate to degrade mRNA of the endogenous target gene, thus preventing gene 
expression. During the process of degradation, mRNA comes in between the N-terminal and 
the PAZ domain and goes out between the PAZ domain and the middle domain. When 
mRNA moves between the PAZ domain and the “crescent basin”, it is cleaved by the active 
site of the PIWI domain.  
RISC can be recycled. When a target mRNA is degraded, RISC can continue to degrade 
other target mRNA, thus amplifying the PTGS effect of the target gene (Gregory et al, 2005) 
and this amplification can maintain for few days in dividing cells. Obviously, it is 
advantageous over other therapeutic methods, and is a potent method for specific inhibition 
of gene expression. In addition, a few studies(Meister et al, 2005) also found that RISC also 
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has some other protein components, including Vasa intronic gene (VIG) protein, DmFXR, 
Tudor-SN, potential RNA helicase Dmp68 and Gemin3. These proteins are not necessary for 
the activity of RISC nuclease, but may provide additional functions such as RISC turnover, 
RISC subcellular location, and degradation after mRNA cleavage.  
2.2 Mechanisms of miRNA 
miRNAs are a class of endogenous non-coding RNA that serves a specific function in 
eukaryotic organisms, with about 20~25 nucleotides. Mature miRNAs are processed from 
relatively long primary transcripts through a series of nuclease cutting, and then assembled 
into the RNA-induced silencing complex to identify target mRNA through base pairing, and 
instruct the silencing complex to degrade or block the translation of target mRNA 
depending on the degree of complementation. 
miRNA genes are usually transcribed by RNA polymerase II (pol II) in the nucleus, and the 
primary product is pre-miRNA with a large cap-structure (7MGpppG) and a poly-A tail 
(AAAAA). Pre-miRNA is treated in stem loop-structured pre-mRNA containing 60-110 
nucleotides in the presence of Rnase III enzyme Drosha (RNASEN) and its cofactor DGCR8 
(a double-strand RNA domain-binding protein)(Tang,2005), and this pre-miRNA is 
transported from the nucleus to the cytoplasm by RAN-GTP and exportin 5 (EXP 5), and 
then cleaved by another nuclease Dicer to produce miRNA:miRNA double strands about 22 
nucleotides in length, which are quickly introduced into RISC containing Ago2. One of the 
single-stranded mature miRNA is retained in the complex and expressed in response to 
regulatory genes in a manner similar to siRNA at the compensatory site of mRNA via base 
pairing (Meister&Tuschl,2004). Apart from Ago2, Ago1, Ago3 and Ago4 in the argonaute 
family that have no endonuclease activity also participate in the RNAi process of RISC 
through regulation on RISC rather than through cleavage (Preall&Sontheimer,2005). 
Identification of target mRNA by miRNA requires precise pairing of nucleotides with 
miRNA seed sequence (Sethupathy et al, 2006). If miRNA and mRNA compensate with each 
other precisely, Ago 2 can cleave mRNA in the same way as it cleaves siRNA (Meister et al, 
2004). However, there is a convex sequence in the middle of the A-type helical structure 
from non-precise combination of compensatory miRNA and the target mRNA, which makes 
mRNA cleavage impossible but can inhibit the expression of target mRNA at the protein 
translation level. This cleavage-independent mechanism plays the main role in miRNA-
nduced RNAi (Pillai et al, 2007). The miRNA-binding site using this mechanism is usually in 
3’-end non-translation region of mRNA. Each miRNA can have multiple target genes, while 
several miRNAs can also regulate the same gene. This complex regulatory network can 
regulate expression of multiple genes through one miRNA, or precisely regulate the 
expression of a particular gene through combination of several miRNAs (Sethupathy et al, 
2006). About one-third of encoding protein mRNA can be regulated by miRNA(Krek et al, 
2005).  
2.3 Mechanisms of shRNA 
shRNA contains two short inverted repeat sequences separated by a stem loop in the middle 
forming a hairpin structure, which is controlled by Pol III promoter and then connects with 
5-6 T as the transcription terminator of RNA Pol III. One of the methods of transporting 
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siRNA in vivo is to clone the siRNA sequence into the plasmid as a “short hairpin”. When 
the hairpin is delivered to the animal body, its sequence is expressed, forming “double-
stranded RNA” (shRNA), which is treated by the RNAi pathway.  
The first-generation shRNA is decorated and cloned to the viral carrier on the pre-miRNA 
platform, and transcribed into 50-70bp single-stranded molecules with the unique “stem-
loop” structure in the presence of RNA Pol III in the nucleus. When it enters the cytoplasm, 
its stem-loop structure is cut off by Dicer, forming siRNAs. Finally, it participates in the 
production of the RISC complex and induces RNAi (Paddison et al, 2004; Brummelkamp et 
al, 2003; Berns et al, 2004). With further research on miRNA, researchers have re-modeled the 
well-known structure of human miRNA-mir-30 and successfully developed a carrier-
mediated second-generation RNAi trigger shRNAmir using pri-miRNA as the platform. 
Unlike pri-mir-30, the “stem” of this carrier-mediated shRNAmir has been replaced by other 
double helixes specific to different target genes. This structural re-design and transformation 
do not affect normal maturity of mir-30. Compared with the first-generation shRNA, the 
design of the second-generation shRNAmir makes use of the endogenous Drosha digestion 
process, thus increasing the specificity of Dicer in identifying Pre-miRNA. In addition, 
shRNAmir enters the intracellular RNAi pathway than shRNA or siRNA and can be treated 
by Drosha and Dicer, thus producing more siRNA(Silva et al, 2005). 
2.4 Mechanisms of bifunctional shRNA 
Bifunctional shRNA can make use of cleavage-dependent and non cleavage-dependent 
RNAi (Rao et al, 2010). Such shRNA contains two stem loops: one with complete-matching 
passenger and guide strands, which can combine with cleavage-dependent RISC, and the 
other with non-matching strands, which can combine with non cleavage-dependent RISC. 
This shRNA is more efficient than shRNA RNAi with one RISC complex. In experiments 
directly comparing the same siRNA target RNAi, it was found that bifunctional shRNA was 
more efficient (the same dosage of shRNA could produce more powerful gene knockout 
function) and its pharmacokinetics also underwent change(Rao et al, 2009,2010). 
3. The application of RNAi for silencing of tumor-related genes 
RNAi has a standard procedure in intracellular gene knockout and can be used to identify 
gene functions by inhibiting specific genes and analyzing the change of gene appearance. As 
such, by analyzing gene functions, the signal pathway of tumor development could be 
identified. This further provides the feasibility to assess the medical or RNAi therapeutic 
target(Devi,2006). In addition, systemic treatment approaches with cancer-related miRNA or 
miRNA offer opportunities for tumor therapy. There have been a few overexpressed target 
genes for RNAi study in vivo. The section is a retrospective review of these targets. 
3.1 Vascular endothelial growth factor 
Vascular endothelial growth factor (VEGF) is a heparin-binding growth factor specific to 
vascular endothelial cells, and can induce angiogenesis in vivo. VEGF and anti-VEGF 
coexist in normal tissues and remain in a relatively balanced state. In the presence of tumor 
growth, multiple carcinogenic factors trigger dramatic increase in VEGF, the amount and 
function of which are by far greater than those of anti-VEGF, thus causing massive growth 
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of vessels (mainly blood vessels) and promoting tumor growth and metastasis. In addition, 
VEGF interferes with and inhibits dendritic cells and blocks antigen presentation of B and T 
cells, which further induces immune escape of tumors, interferes with the normal immune 
function of the body, and causes resistance to anti-tumor therapy. He (He et al, 2009) used 
CaCO3 as the matrix and form nanoscaled complexed with the plasmid to expresses siRNA 
targeting VEGF. In their siRNA transfection against colon cancer cells in vitro, they found 
that this complex could significantly reduce the expression level of VEGF-C in LoVo cells. In 
the experiment with transplanted colon cancer in nude mice, the mean tumor size treated by 
the complexes was decreased by 50% as compared to that in the control group. Metastasis of 
the cancer cells in lymph nodes and lymphatic ducts was also inhibited.  
3.2 Vimentin 
Cell structures and morphologies are maintained through a series of complex structural 
proteins, including microtubules, microfilaments and intermediate filaments. Vimentin is a 
type III intermediate filament. Studies in recent years have demonstrated that vimentin is 
closely associated with tumor development and metastasis, and participates in adhesion, 
migration, invasion and cell signal transduction of tumor cells and tumor-related 
endothelial cells and macrophages. Vimentin possesses a highly dynamic balance between 
polymerization depolymerization and a very complex phosphorylated form, which serve as 
the basis for it to participate in tumor metastasis and intercellular actions. Vimentin is found 
to be homological to most sequences of miR-17-3p in the miRNA gene cluster 17-92 family. 
miR-17-3p participates in regulating the expression of vimentin. miR-17-3p is a known 
tumor-inhibiting gene. It remains at a low level in highly tumorigenic and metastatic cell 
lines and at a high level in cell lines of low tumorigenesis. Zhang (Zhang et al, 2009) used 
plasmds expressing miR-17-3p to intervene transplanted prostate cancer in mice and found 
that the tumor size was only 50% of the control group 31 days after the experiment. They 
also found that vimentin expression was negatively correlated with miR-17-3p expression, 
and the rate of tumor growth was also negatively correlated with miR-17-3p. Paccione RJ 
(Paccione et al, 2008)used vimentin as the target to perform RNA interference3, and found 
that the ability of cell proliferation, metastasis and invasion in cellRNAi group decreased by 
3 fold as compared with the control group. In addition, tumorigenesis of cells treated with 
vimentin-RNAi decreased significantly, and the size of tumors injected subcutaneously with 
vimentin-RNAi was 70% smaller than that of the control group.  
3.3 STAT3 
Signal transducer and activator of transcription 3 (STAT3) is a member of the STAT family, 
participating in signaling pathways closely related to cell proliferation, differentiation and 
apoptosis. Its abnormal activity may promote cell differentiation and proliferation and 
inhibit cell apoptosis, causing tumor development and promoting metastasis of tumor cells. 
It is found to be activated persistently in hepatocellular carcinoma (HCC), breast cancer and 
esophageal squamous cell carcinoma. Li (Li et al, 2009) injected STAT3-target shRNA, 
negative shRNA and normal saline (NS) into transplanted HCC tumors in nude mice and 
removed the tumors after observation for a period. It was found that the tumor tissue in 
STAT3-shRNA, negative shRNA and NS groups was 0.18g, 0.6g and 0.67g respectively. It 
was also found that the expression of STAT3, phosphorylation of STAT3, and expressions of 
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VEGF, survivin and MYC were down-regulated, while caspase3 and p53 were up-regulated 
in STAT3-shRNA group. Huang (Huang et al, 2011)studied the effect of RNAi using STAT3 
as the target gene on pancreatic cancer, and found that STAT3 RNAi not only inhibited 
tumor growth but inhibited angiogenesis in the tumors. They also found that VEGF and 
MMP-2 mRNA and protein levels decreased significantly in SW1990 cells treated with 
RNAi, indicating that STAT3 plays an important role in the course of tumor development 
and progression, and can be used as a target for tumor gene therapy.  
3.4 Human telomerase reverse transcriptase 
Human telomerase reverse transcriptase (hTERT) is a rate-limiting enzyme maintaining the 
activity of telomerase. However, it is found that hTERT not only maintains telomerase but 
stabilizes cell genomes, promotes cell proliferation, inhibits cell apoptosis, and plays a role 
in regulating intracellular signaling pathways. A recent study(de Souza Nascimento et al, 
2006)transfected Hela with shRNA expressing carrier-encoded target shRNA, and found 
that short telomerase-related hTERT mRNA was reduced dramatically, cell growth was 
inhibited, and cell apoptosis was accelerated. A similar study(Gandellini et al, 2007)showed 
that transfection of hTERT specific siRNA with lipofectamine 2000 could inhibit the 
expression of hTERT for a prolonged time, thus affecting the proliferation and 
tumorigenesis of prostate cancer PC-3 cells. 
3.5 Survivin 
Survivin is a recently discovered tumor-specific inhibitor of the apoptosis protein family. 
There is no or micro expression in well differentiated tissues, and high expression in 
embryonic and most human malignant tumor tissues. It inhibits apoptosis of tumor cells, 
thus promoting cell growth and regulating cell division. In addition, it is closely associated 
with infiltration and metastasis of tumor cells. Survivin is found expressing in common 
malignant tumors such as breast cancer, gastric cancer, kidney cancer, melanoma, intestinal 
cancer, neuroblastoma cancer and ovarian cancer. In their retrospective analysis of tumor 
treatment, Kanwar (Kanwar et al, 2010)demonstrated that survivin-targeted molecular 
therapy could inhibit the growth of tumor cells. Recently, Chen (Chen&Deng,2008) injected 
gastric cancer MGC-803 cells treated with plasmids expressing survivin-siRNA and control-
treated plasmids, and those without intervention into nude mice subcutaneously. Four 
weeks later, the mean tumor volume in the intervention group, control group and non-
intervention group was 831mm3, 2617mm3 and 2536mm3 respectively, indicating that the 
apoptosis rate in siRNA intervention group was significantly higher than that in the control 
and non-intervention groups (27.63% vs 2.15% vs 2.31%). In their experiment study with 
survivin-target RNAi for the treatment of urinary bladder cancer, Seth (Seth et al, 2011) 
reported the similar result and further confirmed that survivin-target RNAi could inhibit 
tumor cell growth effectively.  
3.6 ERK-MAPK 
ERK-MAPK is activated in many malignant tumors, and plays a primarily important role 
in cell growth, differentiation and survival. siRNA specific to extracelluar signal 
regulating kinase 1/2 (ERK1/2) could inhibit the proliferation of ovarian cancer cells and 
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induce their apoptosis and death, but it had no effect on normal ovarian cells (Zeng et al, 
2005). Super-expression of epithelial growth factor receptor HER2/neu was detected in 
many breast cancers, but its expression in patients with good prognosis was low. 
Transfection of HER2/neu siRNA led to an antiproliferative and apoptosis-inducing effect 
in breast cancer cells with high expression of HER2, and this effect was not observed in 
cells without HER2 expression, suggesting that interference with HER2 could be used as 
an effective strategy for the treatment of breast cancer with high expression of 
HER2(Faltus et al, 2004).  
3.7 Osteopontin 
Osteopontin (OPN) is a secretory extracellular matrix protein and a cytokine as well. It 
can promote cell chemotaxis, adhesion and migration. More studies (Wai&Kou, 2008; 
Wise & King, 2008;Ramaiah&Rittling,2008) have demonstrated that OPN can interact with 
┙V┚3 and CD44 to participate in cell inflammatory response, promote cell migration, 
adhesion and transduction of related signals, regulate the expression of genes related to 
tumor development and progression, promote degradation of extracellular matrix, 
suppress the immune function of the body against tumors, and accelerate tumor 
progression. Studies(Coppola et al, 2004; Cui et al, 2007;Tang et al, 2007)have found that 
the level of OPN expression is generally increased in lung, gastrointestinal, urogenital and 
gynecological tumors. Zhang (Zhang et al, 2010) used plasmid-mediated OPN-target 
siRNA to transfect lung cancer A549 cells and found that the invasion and proliferation 
abilities of A549 cell decreased. Gong (Gong et al, 2010) used PEI as the carrier of OPN-
siRNA and injected it between tumor tissues in nude mice bearing transplanted gastric 
cancer tumors. It was found that the tumor size of the experiment group was only one-
third of the control group, and survival of the mice was also prolonged (animals in the 
control group survived 40 days, and 50% of the animals in the experiment group 
remained surviving at 60 days).  
3.8 β-catenin 
┚-catenin is a multi-functional adapter protein encoded by human CTNNB1 gene. Its 
function is expressed in two aspects: One is acting as an important component of the Wnt 
signaling pathway to mediate signal movement from the membrane to the cytoplasm and to 
the nucleus, regulating transcription of target genes (such as c-myc,cyclin D1, MMP-7 and 
cyclooxygenase-2). The other is participating in E-cadherin-mediated intercellular adhesion. 
┚-catenin participates in cell growth, proliferation, invasion and metastasis in malignant 
tumor tissues. It was found that ┚-catenin expression was extraordinarily high in many 
tumors, especially in esophageal cancer. Wang (Wang et al, 2009,2010) used ┚-catenin-
targeted RNA to interfere with plasmid pGen-3-CTNNB1 and found that pGen-3-CTNNB1 
could lower the expression level of ┚-catenin in esophageal cancer tissue, and reduce the 
invasion and metastasis abilities of cancer cells. The result of the experiment with nude mice 
bearing transplanted esophageal cancer showed that the mean volume of tumors in ┚-
catenin RNAi plasmid group was 909.3mm3 versus 2684.4mm3 in the negative control group 
and 2722.6mm3 in the non-intervention group, indicating that ┚-catenin-target RNAi could 
inhibit the growth of esophageal cancer tumors.  
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3.9 MYC 
Myc gene is a group of cancer genes discovered earlier, including C-myc, N-myc and L-myc, 
belonging to nucleoprotein-coding cancer gene. All the three genes encode a nuclear DNA-
binding protein related to cell cycle regulation. The Myc gene family and its products can 
promote cell proliferation, immortalization, dedifferentiation and transformation, and play 
an important role in the formation of various tumors. Super-expression of Myc gene has 
been detected in gastric cancer, breast cancer, colon cancer, cervical cancer, Hodgkin's 
disease and head tumors. Zhang (Zhang et al, 2009)injected Myc-target siRNA between 
transplanted colon cancer tissues in nude mice, and found that the expression level of Myc 
decreased by 40%; large patches of necrosed cells were seen in tumor tissues; the 
proliferation of tumor cells was inhibited; and the mean tumor size was about 50% of the 
control group.  
3.10 Epithelial cellular adhesion molecule 
Epithelial cellular adhesion molecule (EpCAM) is a recognized tumor-related protein 
encoded by TACSTDl gene. EpCAM is more than an adhesion molecule, and also has many 
other functions including participation in regulating cell migration, metastasis, 
differentiation, signal transduction, cell cycle and metabolism. Studies have demonstrated 
that EpCAM presents high expression in most solid tumors. In addition, the level of EpCAM 
expression is positively correlated with lymphatic metastasis. Du (Du et al, 2009) transfected 
lipofectamine 2000 with EpCAM-target siRNA to treat two gastric cell lines (AGS and 
SGC7901) in transplanted tumor-bearing nude mice, and found that the size of both tumors 
was about 50% smaller than that of the control group. They also found that the level of 
CCND1 expression in tumor tissues was decreased, and cell division was blocked at G1. 
3.11 CD147 
CD147 is a transmembrane glycoprotein extensively expressing in various tissues of the 
human body, belonging to the immunoglobulin super-family participating in various 
physilogical and pathological processes of the body. CD147 interacts with integrin, central 
avidin, monocarboxylate transporter 1 (MCT1), MCT3 and MCT4 proteins. It is also 
related to the expression of lactate transporters. These proteins may act as candidate 
ligands or receptors of CD147 molecule and mediate the biological function of epithelial 
cells via protein-protein interactions. High expression of CD147 is detected in multiple 
tumor tissues, especially in pancreatic cancer (Zhang et al, 2007), where it promotes 
invasion, metastasis and anchorage-independent growth of tumor cells, and induces 
tumor angiogenesis. Schneiderhan (Schneiderhan et al, 2009) used CD147-target RNAi to 
treat pancreatic cancer cells and found that MCT1 and MCT4 were inhibited in tumor 
cells, and the intracellular concentration of lactate was increased, thus inhibiting the 
growth of tumor cells. In vivo experiments using shRNA-target silencing of CD147 to 
treat transplanted pancreatic cancer tumors in nude mice showed that the tumor size of 
the experiment group was significantly smaller than that of the control group (39.7mm3 vs 
89.7mm3), indicating that CD147 as a helper protein could also be used as the target for 
tumor treatment.  
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3.12 Urokinase-type plasminogen activator 
Urokinase-type plasminogen activator (uPA) is an important component participating in 
degradation of extracellular matrix and plays an important role in invasion and metastasis 
of tumor cells. Super-expression of uPA receptor (uPAR or PLAUR) is detected in many 
malignant tumor cells. Zhou (Zhou et al, 2009) used a retroviral vector carrying siRNA 
expressing target PLAUR to treat transplanted oral squamous cell carcinoma for 30 days, 
and found that the mean tumor size of the intervention group was 1382mm3 versus 
4181mm3 in the NS control group. The number of apoptotic cells in the intervention group 
was significantly greater than that in the control group (32.7 vs 2.7, P<0.01). The expression 
level of u-PAR, MMP2, MMP9, VEGFD, VEGFC and VEGFR-3 in the intervention group 
decreased significantly, and proliferation-related Ki-67 was inhibited.  
3.13 P21-activated kinase 6 
Super-expression of P21-activated kinase 6 (encoded by PAK6) is detected in malignant 
prostate cancer tissues. Wen (Wen et al, 2009) compared the inhibitory effect of PAK6-target 
siRNA (by intratumor injection in transplanted pancreatic cancer tumor-bearing nude mice) 
and Taxol on tumors, where siRNA was injected into tumors of transplanted pancreatic 
cancer-bearing nude mice. The result of six-week observation showed that the mean tumor 
size of the control group, Taxol group, siRNA group and Taxol+siRNA group was 475mm3, 
210mm, 68mm3 and 47mm3 respectively. PAK6-siRNA inhibited the growth of pancreatic 
cancer cells and blocked them at G2-M, demonstrating that both Taxol and PAK6-siRNA 
could inhibit tumor growth. The inhibitory effect of combined use of Taxol and PAK6-
siRNA was significantly better than either of the two along.  
3.14 Skp-2 
Skp-2 is a substrate recognition subunit of ubiquitin-protein ligase complex SCF/Skp-2, high 
expression of which in many tumors suggests a poor prognosis. Increased Skp-2 is believed 
to be associated with cell cycle disturbances in many tumors. HIV retroviral vector-
mediated RNAi inhibited Skp-2 high expression cells effectively by increasing the 
expression of p27 and p21, but it had no significant effect on Skp-2 low expression 
cells(Sumimoto et al, 2005). Intervention of Skp-2 expression in 90% A549 and H1792 lung 
cancer cell strains could reduce p27 expression, induce apoptosis and inhibit proliferation 
(Simpson et al, 2004). Subcutaneous injection of the adenoviral vector of Skp-2 RNAi could 
inhibit the growth of subcutaneously transplanted lung cancer effectively, but it was 
ineffective in tumors without high expression of Skp-2(Faltus et al, 2004). Sumimoto et al 
(Sumimoto et al, 2006) also found that interference with Skp-2 and BRAFD expression could 
inhibit the growth and invasion of melanoma cells in vitro.  
3.15 Cytokine-induced apoptosis-inhibiting molecule  
Cell apoptosis is programmed cell death regulated by multiple genes. Cytokine-induced 
apoptosis inhibitor 1 (CIAPIN1) is an important regulator of cell apoptosis. It has a 
significant inhibitory effect on multiple links in cell apoptotic pathways and a positive 
regulatory effect on Ras and other survival signaling pathways, thus promoting cell survival 
and proliferation (Shibayama et al, 2004). In recent years, many studies on the relationship 
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between CIAPIN1 and tumor formation showed that CIAPIN1 expression was increased 
significantly in HCC, gastric cancer and other malignant tumor tissues (Ida et al, 2007;Zhang 
et al, 2008). Li (Li et al, 2008) used adenovirus-mediated RNAi to knock out CIAPIN1 in HCC 
cells and found that CIAPIN1 gene expression in HCC cells was down-regulated, where 
cells were prevented from entering phase S and cell proliferation was inhibited. Eight weeks 
after injection of adenovirus/siRNA between transplanted tumor tissues, the tumor size was 
only one-sixth of the control group, and pathological sections showed apoptotic cells in 
tumor tissues.  
3.16 Eukaryotic initiation factor 4E 
Available studies showed that any form of genetic variation should function at the protein 
level (Branhart&Simon, 2007). Therefore the relationship between eukaryotic cell (protein 
translation) initiation factor and tumors has aroused increasing attention, especially 
eukaryotic initiation factor 4E (eIF4E), which was believed to be more closely related to 
tumors (Sonenberg,2008). Data have shown that eIF4E can alter the amount of expression of 
some malignant tumor-related genes and is the determinant of malignant phenotype 
production. It promotes cells to surpass the limit of normal growth and undergo 
carcinogenesis through regulating the amount of translation of some specific malignancy-
related molecules (Culjkovic et al, 2006). Dong (Dong et al, 2009) used a vector carrying 
shRNA of survivin-targeted eIF4E to transfect human breast cancer cells, and found that not 
only the level of eIF4E mRNA and protein expression was decreased but tumor progression-
related protein VEGF, FGF2 and CCND1 were also down-regulated markedly. The breast 
cancer tumor size of the intervention group using eIF4E-targeted shRNA was significantly 
smaller than that of the control group (233.5mm3 vs 397.7mm3, P<0.01). In addition, shRNA 
could also enhance the chemotherapy effect of cisplatin. The result showed that the tumor 
size of the cisplatin+shRNA plasmid combination group was significantly smaller than that 
of the plasmid control group (134.5mm3 vs 208.9mm3, P<0.01).  
3.17 Erythropoietin 
Erythropoietin (EPO) was initially found to play a main regulatory role in the 
proliferation and differentiation of erythroid cells. Studies have shown that t EPO and 
erythropoietin receptor (EPOR) are expressed in many different nonhematopoietic organs 
and tissues, playing a role in promoting angiogenesis and protecting tissues. Many recent 
studies have discovered extensive expressions of EPO and EPOR in many malignant 
tumors, the autocrine/paracrine pathways of which are associated with tumor 
microangiogenesis, stimulation of tumor cell proliferation and sensitivity to 
chemotherapy. In addition, Paragh(Paragh et al, 2009) found that EPOR had a function 
independent of EPO in tumors. It was found that EPOR was highly expressed in ovarian 
cancer A2780 cell line, but no expression of EPO was observed in normal or hypoxic 
conditions. Use of exogenous EPO to intervene 2780 cells did not alter their biological 
effect. Paragh(Paragh et al, 2009) transplanted ovarian cancer cells treated with EPOR-
target shRNA and those with a negative control vector in mice subcutaneously for 7 
weeks, and found that the mean tumor size of the negative control group was 10-fold 
larger than that of the intervention group. This difference in tumor size is mainly due to 
decreased cell proliferation in the intervention group. However, the apoptotic rate was 
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similar between the two groups, indicating that EPOR plays a role in regulating cell 
proliferation, and this effect is independent of EPO. 
3.18 miR-221 and miR-222 
miR-221 and miR-222 are miRNA in cluster distribution with high homogeneity. Studies 
have shown that tumor suppressor gene p27 (Fornari et al, 2008), p57(Fornari et al, 2008), 
pro-apoptotic factor Bim and Bmf (Gramantieri et al, 2009) are all target genes of mir-
222/mir-221. studies in recent years have shown that miR-221and miR-222 participate in the 
development of bladder cancer, HCC, prostate cancer and melanoma. Artificially 
synthesized small RNA precisely compensatory with miRNA can be used as an miRNA 
inhibitor to silence endogenous miRNA. Mercatelli et al (Mercatelli et al, 2008) used anti 
miR-221 and anti miR-222 inhibitors and a negative control inhibitor to intervene 
transplanted prostate cancer in nude mice for 33 days, and found that the means tumor size 
of the intervention group and the control group was 197.2mm3 and 276.82mm3 respectively, 
indicating that regulation of miR221/222 via RNAi could be used as the target of tumor 
treatment. 
3.19 miR-16 
miR-16 can target Oncogene BCL-2. By regulating BCL-2 expression with miR-16, tumor cell 
proliferation can be inhibited. Schaefer et al (Schaefer et al, 2010) found that miR-16 can 
down-regulate BCL-2 expression in prostate cancer cells. Takeshita et al (Takeshita et al, 
2010) used chemically synthesized miR-16 to transfect prostate cancer cell line 22Rv1, 
Du145, PPC-1 and PC-3M-luc, and found that the proliferation of these cells was inhibited. 
They administered miR-16 and atelocollagen to prevent bone metastasis from transplanted 
prostate cancer tumor in nude mice via tail vein injection. The results showed that, 
compared to i.v. injection of atelocollagen as a positive control, miR-16 halted the 
progression of the transplanted tumors and metastatic lesions, and that miR-16 could 
regulate the expression of CDK1 and CDK2 that participate in cell cycle and proliferation. 
Therefore, intravenous administration of miR-16 could be applied as a strategy for the 
treatment of advanced prostate cancer.  
3.20 miR-26a 
miR-26a is an miRNA that plays role of tumor suppressor gene. Lu (Lu et al, 2011) found 
that miR-26a could down-regulate the level of EZH2 expression in nasopharyngeal cancer 
cells, inhibit cell proliferation significantly, and block cell division at G1. Kota et al (Kota et 
al, 2009) used miR-26a to intervene HCC, and found that miR-26a could down-regulate the 
level of cyclin CCND2 and CCNE2 expression, inhibit the proliferation of HCC cells in vitro, 
and inhibit tumor progression in vivo, indicating that miR-26a could be used as a strategy 
for tumor treatment by down-regulating cancer genes.  
3.21 Specific mutation ectopic gene  
1. Ras: Ras is the gene that is most likely to undergo mutation in human malignant 
tumors. A single-point mutation is enough to transform normal protein into cancer 
protein. Therefore, there is mild difference in DNA sequence between the wild-type Ras 
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and mutated-type Ras. Previous methods of gene therapy were unable to inhibit the 
expression of mutated-type Ras effectively. Researchers have succeeded in using 
retrovirus-mediated RNA intervention technique to inhibit the expression of mutant K-
rasV12 without affecting the other Ras subtypes (Brummelkamp et al, 2002). It not only 
inhibited neoplastic growth and transformation in experiments in vitro but obtained the 
same result in animal models.  
2. bcr-abl: chronic myeloid leukemia (CML) is associated with chromosomal translocation. 
Protein tyrosine kinase encoded by fusion gene bcr-abl formed durin translocation 
plays a very important role in the development of CML. Many studies on bcr-abl 
interference showed that the interference was effective on fusion gene, as shown by 
down-regulated expression of bcr-abl protein expression, inhibition on cell growth and 
apoptosis, increased sensitivity to the anti-cancer agent imatinib mesylate, while it had 
no effect on the wild-type gene in normal tissues. Koldehoff et al (Koldehoff et al, 2007) 
first reported the successful use of bcr-abl siRNA in the human body. It enhanced the 
sensitivity to the anti-cancer agent imatinib mesylate, inhibited the expression of bcr-
abl, and promoted cell apoptosis. However, siRNA directing at bcr-abl homologous 
chromosomes could not enhance the sensitivity to imatinib mesylate and had no effect 
at all(Lima et al, 2004). The reason may be due to different degrees of down-regulation 
of bcr-Abl protein expression by the siRNA.  
3. p53: 50% tumors have mutated-type p53, which attenuates the function of the wild-
type. Inhibiting the expression of the mutated-type p53 can help recover the function of 
the wild-type. A large-scale study on loss of gene function by using RNA 
Databank(Berns et al, 2004) revealed one known and five new p53-dependent 
hyperplasia suppressor genes (HSG). Inhibition on the expression of these genes can 
counteract the anti-proliferation function of p53and p19ARF, and thus remove G1 arrest 
arising from DNA injury.  
4. Clinical trials 
Local and systemic drug administrations are the main routes of drug delivery in current 
clinical trials in vivo. Local drug administration depends on the type of target tissue, 
including intravitreal injection for ophthalomological diseases; intranasal administration for 
respiratory diseases caused by respiratory syncytial virus; intracranial injection for central 
nervous system diseases; intratumor injection for carcinogenic genes; and intramuscular 
injection for muscle tissue diseases such as rheumatoid arthritis. Drugs delivered by local 
administration can directly act on the target organ, thus reducing the probability of 
degradation of siRNA by nuclease and the dosage of siRNA. Systemic drug administration 
mainly depends on intraperitoneal and intravenous injection. Systemic drug administration 
often needs more siRNA to enable the target organ or tissue to obtain an efficacious drug 
concentration.  
A lot of studies have demonstrated that RNAi has substantial potential for tumor treatment. 
Several RNAi agents have entered clinical trials in the world (Table 1). In May 2008, RNAi 
agent CALAA-01 for the treatment of solid tumors, developed by Calando Pharmaceuticals, 
was approved by the Food and Drug Administration (FDA) of the United States for Phase I 
clinical trial. CALAA-01 is a complex of siRNA and cyclodextrin-transferrin-adamant-PEG 
nanoparticles, in which human transferrin can specifically interact with transferrin receptor 
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that is overexpressed on the tumor cell membrane, thereby triggering the entry of the 
nanoparticles into tumor cells through receptor-mediated endocytosis. The target gene is 
ribonucleotide reductase subunit 2 (RRM2). After systemic administration by i.v. injection, 
siRNA efficiently inhibited tumor growth by down-regulating RRM2 expression 
(Davis,2009). It was also found that the levels of RRM2 mRNA and RRM2 protein were both 
decreased in the tumor. To detect the efficiency of RNAi, researchers found that there 
existed large amounts of RRM2 mRNA degradation products at tumor site containing the 
nanoparticles(Davis et al, 2010). This is the first clinical trial on RNAi medical treatment of 
malignant tumors.  
 
SiRNA agent Company/Institution Target Disease Clinical 
Trials 
CALAA-01 Calando 
Pharmaceuticals 
RRM2 Solid tumor Phase II 
ALN-VSP02 Alnylam KSP, VEGF hepatocarcinoma Phase II 
Anti-tat/rev 
shRNA 
Benitec&The city of 
Hope National 
Medical Center 
Tat & Rev from 
HIV 
AIDS-related 
lymphoma 
Phase I 
Atu027 Silence Therapeutics PKN3 Pulmonary 
carcinoma 
Phase I 
BCR-ABL 
siRNA 
University of 
Duisburg-Essen 
Bcr-able Chronic myeloid 
leukemia 
Single 
patient 
FANG Gradlis, Inc. Furin Advanced 
cancer 
Phase I 
SV40/BCR-ABL Hadassah Medical 
Organization 
Bcr-abl Chronic myeloid 
leukemia 
Phase I 
siRNA 
immunotherapy
Duke University 
Hospital 
Proteasome Metastatic 
melanoma 
Phase I 
Table 1. A summary of current siRNA agent for clinical trials 
Alnylam Pharmaceuticals (Alnylam Pharmaceuticals,2011a,2011b) conducted Phase I clinical 
trial by intravenous administration of ALN-VSP02 for the treatment of HCC, where the 
siRNA therapeutic was enveloped in liposome. A total of 58 patients were recruited in the 
study and administered with the therapeutic at an interval of two weeks. The therapeutic 
agent targets kinesin spindle protein (KSP) and VEGF that are highly expressed in tumor 
cells. KSP plays a key role in cell mitosis and is the dynein necessary for bipolar spindle 
formation and maintenance. Inhibition of KSP would arrest the cell cycle. VEGF promotes 
angiogenesis, and therefore inhibition of VEGF would suppress tumor growth. Currently, 
Phase I clinical trial with ALN-VSP02 has been done, and Phase II clinical trial is to be 
started in 2012.  
Recently, Silence Therapeutics has started Phase I clinical trial on Atu027(Aleku et al, 2008; 
Santel et al, 2010). Atu027 is a lipid-based siRNA complex containing target protein kinase 
N3 (PKN3), which participates in tumor occurrence and plays an important role in tumor 
metastasis. Atu027 can inhibit tumor progression by silencing the expression of PKN3. Pre-
clinical experiments demonstrated that Atu027 could prevent breast cancer cells from 
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spreading to the lungs in mice. In addition, Atu027 could apparently inhibit the growth of 
transplanted prostate cancer in nude mice, where the tumor size was about 50% that of the 
control group; the number of metastatic lymph nodes was only 50% that of the control 
group; and the lymphatic density in the tumor area was also decreased markedly, though 
there was no significant difference in vascular density in the tumor area between the study 
and control groups. In a toxicity experiment, the researchers injected different doses (0.3, 1.0 
and 3.0mg/kg) of Atu027 to different groups of cynomolgus monkeys at a 4-day interval, 
and no significant toxic and adverse effects were observed. Phase I clinical trial with Atu027 
mainly showed safety, tolerance and pharmacokinetics. 
5. Conclusion 
The understanding of signaling pathways participating in the development and progression 
of malignant tumors and the development of specific target RNAi technique have offered 
hope to conduct individualized regimens for tumor treatment. However, current RNAi 
therapeutic approaches are immature and many problems need to be tackled, such as 
targeting and off-target effects, drug delivery systems, drug administrations and safety. As 
siRNA with a sequence of only 20-nucleotides could induce a tremendous effect of gene 
silencing, the sequence of siRNA must be selected accurately in the process of designing 
siRNA sequences to avoid the off-target effect. Additionally, a mRNA target sequence may 
hide in the mRNA secondary structure or folding region, making it impossible for siRNA to 
silence the mRNA. It is therefore necessary to conduct experiments repeatedly to select a 
suitable target site. Before RNAi medical treatment can be used clinically, it is necessary to 
seek an efficient delivery system and rational drug administration. In addition, as nucleotide 
sequences used for RNAi have no cell targetability and are likely to degrade, it is necessary 
to design and synthesize a drug delivery system that is non- or low toxic to normal cells and 
can deliver siRNA to tumor cells efficiently.  
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